Intrexon | XON - Assets


Intrexon reported $73.16M in Assets for its fiscal quarter ending in June of 2024.





Assets Change Date
Agenus USD 186.46M 40.34M Mar/2026
Alaunos Therapeutics USD 1.88M 1.08M Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
Anika Therapeutics USD 179.39M 10.88M Mar/2026
Arrowhead Research USD 2.27B 664.08M Mar/2026
AstraZeneca USD 114.02B 59M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Gilead Sciences USD 56.28B 2.74B Mar/2026
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
Heron Therapeutics USD 246.22M 9.66M Mar/2026
Incyte USD 7.34B 381.14M Mar/2026
Intrexon USD 73.16M 77.88M Jun/2024
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025
Ligand Pharmaceuticals USD 1.53B 28.53M Mar/2026
MacroGenics USD 217.87M 38.97M Mar/2026
MannKind USD 744.4M 47.78M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Thermo Fisher Scientific USD 113.28B 2.94B Mar/2026
Veracyte USD 1.44B 30.38M Mar/2026
Xencor USD 736.85M 138.65M Mar/2026